Ampersand buys AccuMed after merger talks fail:
This article was originally published in Clinica
AccuMed has signed a definitive agreement to be acquired by Ampersand Medical in a share deal, three months after Ampersand terminated merger negotiations between the two companies. At that time, the companies agreed to discuss further possibilities (see Clinica No 938, p 12). Ampersand is a cancer diagnostic company and uses AccuMed's AcCell automated microscopy technology in clinical trials of its InPath cervical cancer detection system. Both companies are based in Chicago.
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.